Advanced development of multivalent vaccine candidates for filovirus and lassa fever
Active Definitive Contract Awarded Last action
- Contract number
- 75N93020C00040
- Awardee
-
Auro Vaccines LLC UEI JCL5JKNMYAU5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,706,003
Award facts
- Opportunity
-
- BAANIAIDNIHAI2016064 Solicitation number
- Contract value 41% obligated
-
- $10,706,003.10 Current, with exercised options
- $26,398,540.94 Potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Baltimore, MD 21224, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$22,080 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $6,800 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $55,116 | |
| Supplemental Agreement for work within scope | -$16,900 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | -$33,783 | |
| Supplemental Agreement for work within scope | $700,759 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $1,748,069 | |
| Supplemental Agreement for work within scope | $2,347,352 | |
| Other Administrative Action | $0 | |
| Funding Only Action | -$14,594 | |
| Supplemental Agreement for work within scope | -$6,413 | |
| Exercise an Option | $100,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $986,612 | |
| Original award | $4,855,064 |
Show all 19
About this award
The National Institute of Allergy and Infectious Diseases awarded a definitive contract to Auro Vaccines LLC for advanced development of multivalent vaccine candidates for filovirus and Lassa fever on July 21, 2020, with a ceiling value of $26.4 million under cost-plus-fixed-fee pricing and no set-aside.
The contract supports de-obligation of unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), with ultimate completion by December 31, 2026. Place of performance is Baltimore, MD.
The contract footprint reflects declining labor intensity in recent performance. FY2025 invoiced $2.2 million against 3.0 FTEs and 6,159 contractor hours, compared to FY2024's $3.4 million across 5.2 FTEs and 10,880 hours. The derived government-paid hourly rate rose from $275.46 in FY2023 to $358.57 in FY2025, reflecting a consistent upward pricing trend. Subcontracting depth increased significantly; FY2025 shows 84% of contractor hours subcontracted out through one reported subcontractor.
Quick answers
Who was awarded contract 75N93020C00040?
75N93020C00040 was awarded to Auro Vaccines LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 21, 2020.
How much is contract 75N93020C00040 worth?
The government has obligated $10,706,003 on 75N93020C00040. Its potential value, with all options, is $26,398,541.
Was contract 75N93020C00040 competed?
The extent of competition for 75N93020C00040 was full and open competition. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award